4
Changes in Ownership
Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000077
General Counsel sold 52,000 shares at an average $108.49 ($5,641,409)
- General Counsel acquired 52,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Quinlan Paul T · General Counsel
Table I: Non-derivative
8 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-08-14 | Exercise or conversion : show line 1 in the form 10b5-1 | +10,000 | $7.80 | $78,000 | 41,034 | D |
| 2026-08-14 | Exercise or conversion : show line 2 in the form 10b5-1 | +42,000 | $12.50 | $525,000 | 83,034 | D |
| 2026-08-14 | Sale : show line 3 in the form 10b5-1 | −3,630 | $106.05 | $384,963 | 79,404 | D |
| 2026-08-14 | Sale : show line 4 in the form 10b5-1 | −10,434 | $107.14 | $1,117,901 | 68,970 | D |
| 2026-08-14 | Sale : show line 5 in the form 10b5-1 | −14,696 | $107.97 | $1,586,779 | 54,274 | D |
| 2026-08-14 | Sale : show line 6 in the form 10b5-1 | −10,200 | $109.11 | $1,112,954 | 44,074 | D |
| 2026-08-14 | Sale : show line 7 in the form 10b5-1 | −9,193 | $110.00 | $1,011,266 | 34,881 | D |
| 2026-08-14 | Sale : show line 8 in the form 10b5-1 | −3,847 | $111.14 | $427,547 | 31,034 | D |
| Open-market sales · 52,000 sh · avg $108.49 · $5,641,409 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-08-14 | Exercise or conversion : show line 9 in the form 10b5-1 Employee Warrant (right to buy) | −10,000 | 89,996 | D |
| 2026-08-14 | Exercise or conversion : show line 10 in the form 10b5-1 Employee Stock Option (right to buy) | −42,000 | 120,500 | D |
Loading xslF345X06/form4.xml…